Thu, Jul 24, 2014, 2:00 AM EDT - U.S. Markets open in 7 hrs 30 mins

Recent

% | $
Click the to save as a favorite.

EntreMed, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • semiequipmentgodoftheyear semiequipmentgodoftheyear May 30, 2005 8:35 PM Flag

    BusinessWeek

    EntreMed could not ask for a better investor/partner!CELG is the single largest shareholder in EntreMed.

    Celgene (CELG ): Reiterates 4 STARS (buy)
    Analyst: Frank DiLorenzo, CFA )

    Novartis gets the FDA okay for Focalin XR to treat attention deficit hyperactivity disorder. Celgene is entitled to royalties. We think Celgene's guidance for $60 million in Ritalin-related royalties for 2005 is achievable. We expect approval for Thalomid to treat multiple myeloma and Revlimid to treat myelodysplastic syndrome patients with 5q chromosomal deletion by 2005 end. We see 2005 and 2006 earnings per share at 56 cents and 94 cents. Based on net present value analysis, our 12-month target price is $50. We think Celgene's 1.4 times p-e-to-growth is attractive, on our 2006 earnings per share and 30.5% earnings per share growth estimates.

 
ENMD
1.740.00(0.00%)Jun 13 3:59 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.